Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesBotsEarnCopy
Sonnet BioTherapeutics to merge into Hyperliquid Strategies in $888 million deal

Sonnet BioTherapeutics to merge into Hyperliquid Strategies in $888 million deal

CryptopolitanCryptopolitan2025/07/14 17:50
By:By Florence Muchai

Share link:In this post: Sonnet BioTherapeutics to merge with Rorschach I LLC in a $888 million deal. New entity will hold $583 million in HYPE tokens and $305 million in cash to build a leading crypto treasury. Leadership includes Bob Diamond and David Schamis; Sonnet to continue select biotech operations under HSI.

Nasdaq-listed biotech firm Sonnet BioTherapeutics announced Monday a $888 million merger agreement with Rorschach I LLC, an entity formed by crypto businesses. The merger will change Sonnet’s focus from biotechnology to crypto treasury management under Hyperliquid Strategies Inc. (HSI), which will hold Hyperliquid Layer-1 blockchain’s token HYPE.

The agreement, known as the Business Combination Agreement (BCA), was formally approved by the boards of both companies and is expected to close in the second half of 2025, pending shareholder approval and standard regulatory conditions.

Hyperliquid treasury and focus on HYPE

Upon closing, the combined company will operate under the new name Hyperliquid Strategies Inc. and continue to trade on the Nasdaq Capital Market under a new ticker. 

HSI will hold approximately 12.6 million HYPE tokens, valued at around $583 million based on recent prices, alongside a minimum of $305 million in invested cash. The reserves will bring the company to a combined valuation of  $888 million.

The transaction conjoins a consortium of investors including Paradigm, Galaxy Digital, Pantera Capital, Republic Digital, D1 Capital, and 683 Capital. The cash component of the deal will be used to acquire additional HYPE tokens .

According to the terms of the deal, Sonnet will become a wholly owned subsidiary of HSI and will retain some of its biotech operations while divesting other assets. Its biotech development program, SON-1010, will continue, supported by capital raised from the merger process.

See also BNB Chain gains TradFi traction as xStocks tokenizes leading US equities

Sonnet executive shakeup post merger

The startup leadership team will feature Bob Diamond, co-founder and CEO of Atlas Merchant Capital, as chairman of the board. David Schamis, Atlas’s Chief Investment Officer and Co-founder, will become Chief Executive Officer of HSI. 

We are delighted by this opportunity to partner with Sonnet in establishing a leading crypto treasury management strategy to ultimately deliver strong value to shareholders. We believe HYPE and the Hyperliquid protocol represent a truly differentiated offering within the digital asset space,” incoming board executive Diamond said in a press conference on Monday. 

A new Chief Financial Officer is expected to be named soon, while the board will expand to include Eric Rosengren, former President of the Boston Federal Reserve, and two of Sonnet’s existing independent directors.

At the time of closing, HSI will also enter into a Sponsor Advisory Agreement (SAA) with Rorschach to expand the business by adding HYPE into the treasury.

Capital raised and private placement details

Concurrent with the signing of the BCA, Sonnet is raising $5.5 million in a private placement to accredited investors. The technology company is issuing non-voting convertible preferred stock and warrants to purchase common stock. The placement is expected to close later on today.

An additional $2 million in convertible notes issued by Sonnet in June 2025 will convert into preferred stock and warrants as part of the same transaction. Net proceeds from these offerings will be used for general corporate purposes, including the development of existing biotech assets and expenses related to the Business Combination.

See also BOE Governor Bailey openly disagrees with Trump admin's backing of stablecoins

Ownership of HSI will be weighted toward Rorschach and new investors, who are projected to hold about 98.8% of the company. Existing Sonnet shareholders, including PIPE and bridge investors, will hold approximately 1.2%.

Chardan is the sole placement agent for the transaction and exclusive financial advisor to Rorschach. Greenberg Traurig, LLP is providing legal counsel to Rorschach, while Lowenstein Sandler LLP is representing Sonnet. Additionally, Lucid Capital Markets, LLC, is delivering a fairness opinion to Sonnet’s board.

The securities offered in the private placement are exempt from registration under the Securities Act of 1933 and may not be publicly traded unless registered or covered by another exemption.

KEY Difference Wire : the secret tool crypto projects use to get guaranteed media coverage

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Locked for new tokens.
APR up to 10%. Always on, always get airdrop.
Lock now!